These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33841409)

  • 1. Structural Basis of VSIG3: The Ligand for VISTA.
    Xie X; Chen C; Chen W; Jiang J; Wang L; Li T; Sun H; Liu J
    Front Immunol; 2021; 12():625808. PubMed ID: 33841409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VSIG-3 as a ligand of VISTA inhibits human T-cell function.
    Wang J; Wu G; Manick B; Hernandez V; Renelt M; Erickson C; Guan J; Singh R; Rollins S; Solorz A; Bi M; Li J; Grabowski D; Dirkx J; Tracy C; Stuart T; Ellinghuysen C; Desmond D; Foster C; Kalabokis V
    Immunology; 2019 Jan; 156(1):74-85. PubMed ID: 30220083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure and Functional Binding Epitope of V-domain Ig Suppressor of T Cell Activation.
    Mehta N; Maddineni S; Mathews II; Andres Parra Sperberg R; Huang PS; Cochran JR
    Cell Rep; 2019 Sep; 28(10):2509-2516.e5. PubMed ID: 31484064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The VISTA/VSIG3/PSGL-1 axis: crosstalk between immune effector cells and cancer cells in invasive ductal breast carcinoma.
    Olbromski M; Mrozowska M; Piotrowska A; Smolarz B; Romanowicz H
    Cancer Immunol Immunother; 2024 Jun; 73(8):136. PubMed ID: 38833004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A small molecule inhibitor of VSIG-8 prevents its binding to VISTA.
    Chen W; Qie C; Hu X; Wang L; Jiang J; Liu W; Liu J
    Invest New Drugs; 2022 Aug; 40(4):690-699. PubMed ID: 35404016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and human VISTA.
    Mehta N; Maddineni S; Kelly RL; Lee RB; Hunter SA; Silberstein JL; Parra Sperberg RA; Miller CL; Rabe A; Labanieh L; Cochran JR
    Sci Rep; 2020 Sep; 10(1):15171. PubMed ID: 32938950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, Synthesis, and Antitumor Activity Evaluation of Novel VISTA Small Molecule Inhibitors.
    Sun C; He Y; Wang G; Zhang G; Zhang Y; Shen H; Hu L; Sun Y; Jiang B; Wang X; Yuan K; Min W; Wang L; Sun H; Xiao Y; Yang P
    J Med Chem; 2024 Mar; 67(5):3590-3605. PubMed ID: 38412237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VISTA: A Mediator of Quiescence and a Promising Target in Cancer Immunotherapy.
    Yuan L; Tatineni J; Mahoney KM; Freeman GJ
    Trends Immunol; 2021 Mar; 42(3):209-227. PubMed ID: 33495077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VISTA is an immune checkpoint molecule for human T cells.
    Lines JL; Pantazi E; Mak J; Sempere LF; Wang L; O'Connell S; Ceeraz S; Suriawinata AA; Yan S; Ernstoff MS; Noelle R
    Cancer Res; 2014 Apr; 74(7):1924-32. PubMed ID: 24691993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA.
    Li TT; Jiang JW; Qie CX; Xuan CX; Hu XL; Liu WM; Chen WT; Liu J
    BMC Immunol; 2021 Aug; 22(1):55. PubMed ID: 34380434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Optimization of Small-Molecule Ligands for V-Domain Ig Suppressor of T-Cell Activation (VISTA).
    Gabr MT; Gambhir SS
    J Am Chem Soc; 2020 Sep; 142(38):16194-16198. PubMed ID: 32894020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses.
    Wang L; Rubinstein R; Lines JL; Wasiuk A; Ahonen C; Guo Y; Lu LF; Gondek D; Wang Y; Fava RA; Fiser A; Almo S; Noelle RJ
    J Exp Med; 2011 Mar; 208(3):577-92. PubMed ID: 21383057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VISTA is an acidic pH-selective ligand for PSGL-1.
    Johnston RJ; Su LJ; Pinckney J; Critton D; Boyer E; Krishnakumar A; Corbett M; Rankin AL; Dibella R; Campbell L; Martin GH; Lemar H; Cayton T; Huang RY; Deng X; Nayeem A; Chen H; Ergel B; Rizzo JM; Yamniuk AP; Dutta S; Ngo J; Shorts AO; Ramakrishnan R; Kozhich A; Holloway J; Fang H; Wang YK; Yang Z; Thiam K; Rakestraw G; Rajpal A; Sheppard P; Quigley M; Bahjat KS; Korman AJ
    Nature; 2019 Oct; 574(7779):565-570. PubMed ID: 31645726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy.
    Zhou X; Khan S; Huang D; Li L
    Front Immunol; 2022; 13():938470. PubMed ID: 36189222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the VISTA of microglia: immune checkpoints in CNS inflammation.
    Borggrewe M; Kooistra SM; Noelle RJ; Eggen BJL; Laman JD
    J Mol Med (Berl); 2020 Oct; 98(10):1415-1430. PubMed ID: 32856125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
    Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
    Front Immunol; 2020; 11():563044. PubMed ID: 33250890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The expression and immunoregulation of immune checkpoint molecule VISTA in autoimmune diseases and cancers.
    Wang G; Tai R; Wu Y; Yang S; Wang J; Yu X; Lei L; Shan Z; Li N
    Cytokine Growth Factor Rev; 2020 Apr; 52():1-14. PubMed ID: 32057701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Therapeutic Targets of B7 Family in Colorectal Cancer.
    Wang C; Feng H; Cheng X; Liu K; Cai D; Zhao R
    Front Immunol; 2020; 11():681. PubMed ID: 32477326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression.
    Xu W; Dong J; Zheng Y; Zhou J; Yuan Y; Ta HM; Miller HE; Olson M; Rajasekaran K; Ernstoff MS; Wang D; Malarkannan S; Wang L
    Cancer Immunol Res; 2019 Sep; 7(9):1497-1510. PubMed ID: 31340983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the V-Type Immunoglobulin Domain-Containing Suppressor to T Cell Activation (VISTA) with Agonist Monoclonal Antibodies in Autoimmunity.
    Jung M; Bonavida B
    Crit Rev Immunol; 2022; 42(4):37-49. PubMed ID: 37022358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.